Insider · CIK 0001863614
Scott C. Brun
director
Files at FBRX (Forte Biosciences, Inc.), CABA (Cabaletta Bio, Inc.), JSPR (Jasper Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 3, 2025 | JSPR Jasper Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,500 | $0.00 | $0 | 7,500 | Jul 3, 2025 |
| Jun 9, 2025 | CABA Cabaletta Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | Jun 9, 2025 |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -44,000 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +44,000 | $0.00 | $0 | 44,000 | May 19, 2025 |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 19, 2025 |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -22,000 | $0.00 | $0 | 0 | May 19, 2025 |
| May 19, 2025 | CABA Cabaletta Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +22,000 | $0.00 | $0 | 22,000 | May 19, 2025 |
| Mar 20, 2025 | FBRX Forte Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +31,000 | $0.00 | $0 | 31,000 | Mar 21, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.